At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 123 enrolled
Drug / intervention
Sterile saline +3 moredrug
Likely dose
Sterile saline 0.1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
North American Study of Epistaxis in HHT (NOSE)
In Brief
A Phase 2 clinical trial evaluating Sterile saline, Bevacizumab, and 2 other interventions for Telangiectasia, Hereditary Hemorrhagic and Epistaxis. Completed, enrolled 123 participants across 6 sites.
Detailed Summary
The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of HHT related nosebleeds.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTelangiectasia, Hereditary Hemorrhagic, Epistaxis
CountriesUnited States
CollaboratorsHHT Foundation International
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionSep 2014
TodayJul 2026
First PostedAug 2, 2011
Enrollment StartAug 1, 2011
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.9 years ago
Interventions
Sterile salinedrug
0.9%, 0.1 ml spray in each nostril bid
Bevacizumabdrug
1% solution in saline, 0.1 ml spray in each nostril bid
Estrioldrug
0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
Tranexamic Aciddrug
10% solution in saline, 0.1 ml spray in each nostril bid